| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.39 | 3e-23 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.34 | 5e-18 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.28 | 1e-11 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.24 | 1e-10 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.26 | 2e-10 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.32 | 9e-10 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-09 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.23 | 6e-09 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.23 | 7e-09 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.22 | 1e-08 |